TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Stock Forecast & Price Prediction

Live TransCode Therapeutics, Inc. Stock (RNAZ) Price
$0.26

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$0.26

P/E Ratio

0.00

Volume Traded Today

$516,151

Dividend

Dividends not available for RNAZ

52 Week High/low

128.00/0.22

TransCode Therapeutics, Inc. Market Cap

$5.0M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $RNAZ ๐Ÿ›‘

Before you buy RNAZ you'll want to see this list of ten stocks that have huge potential. Want to see if RNAZ made the cut? Enter your email below

RNAZ Summary

From what 0 stock analysts predict, the share price for TransCode Therapeutics, Inc. (RNAZ) might decrease by 100% in the next year. This is based on a 12-month average estimation for RNAZ. Price targets go from $ to $. The majority of stock analysts believe RNAZ is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

RNAZ Analyst Ratings

TransCode Therapeutics, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that TransCode Therapeutics, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

RNAZ stock forecast by analyst

These are the latest 20 analyst ratings of RNAZ.

Analyst/Firm

Rating

Price Target

Change

Date

Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

Aug 15, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

May 29, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

May 16, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

Apr 16, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

Apr 3, 2024
Emily Bodnar
HC Wainwright & Co.

Buy

$3

Reiterates

Oct 24, 2023
Emily Bodnar
HC Wainwright & Co.

Buy

$12

Reiterates

Aug 15, 2023
Emily Bodnar
HC Wainwright & Co.

Buy

$6

Maintains

Nov 15, 2022
Emily Bodnar
HC Wainwright & Co.

Buy

$10

Initiates

Jun 7, 2022

RNAZ Company Information

  • Company Overview: TransCode Therapeutics, Inc. is a biopharmaceutical company focused on cancer treatment and diagnostics.
  • Lead Therapeutic Candidate: TTX-MC138 targets microRNA-10b, which is crucial for metastatic cell viability in various cancers.
  • Cancers Targeted: The candidate addresses multiple cancer types including breast, pancreatic, ovarian, colon cancers, and glioblastomas.
  • Preclinical Programs:
    • TTX-siPDL1: siRNA-based modulator of programmed death-ligand 1.
    • TTX-RIGA: RNA-based agonist targeting innate immunity in tumors.
    • TTX-CRISPR: CRISPR/Cas9 platform for repairing or eliminating cancer-causing genes.
    • TTX-mRNA: mRNA-based platform for developing cancer vaccines.
  • Strategic Collaboration: The company has a partnership with The University of Texas M. D. Anderson Cancer Center.
  • Incorporation and Location: Founded in 2016 and headquartered in Boston, Massachusetts.
RNAZ
TransCode Therapeutics, Inc. (RNAZ)

When did it IPO

2021

Staff Count

10

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Thomas A. Fitzgerald M.B.A.

Market Cap

$5.0M

TransCode Therapeutics, Inc. (RNAZ) Financial Data

In 2023, RNAZ generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RNAZ's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -208.0%
  • Return on equity TTM -1,048.7%
  • Profit Margin 0.0%
  • Book Value Per Share 0.18%
  • Market capitalisation $5.0M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $268.14

TransCode Therapeutics, Inc. (RNAZ) Latest News

No news data available.

...

RNAZ Frequently asked questions

The highest forecasted price for RNAZ is $ from at .

The lowest forecasted price for RNAZ is $ from from

The RNAZ analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.